Anti-proliferative effect of Cannabidiol in Prostate cancer cell PC3 is mediated by apoptotic cell death, NFκB activation, increased oxidative stress, and lower reduced glutathione status

PLoS One. 2023 Oct 5;18(10):e0286758. doi: 10.1371/journal.pone.0286758. eCollection 2023.

Abstract

Prostate cancer is the second most frequent cancer diagnosed in men in the world today. Almost all prostate cancers are adenocarcinomas and develop from gland cells. We used the PC3 prostate cancer cell line, which is well studied and derived from a bone metastasis of a grade IV prostatic adenocarcinoma. Cannabidiol (CBD), a major non-psychoactive constituent of cannabis, is a cannabinoid with anti-tumor properties but its effects on prostate cancer cells are not studied in detail. Here, we found cannabidiol decreased prostate cancer cell (PC3) viability up to 37.25% and induced apoptotic cell death in a time and dose-dependent manner. We found that CBD activated the caspases 3/7 pathways and increased DNA fragmentation. Furthermore, we observed an increase of pro-apoptotic genes Bax, an increased level of reactive oxygen species, lower reduced glutathione level, and altered mitochondrial potential in response to CBD treatment leading to lower cellular ATP. Overall, our results suggest that CBD may be effective against prostate cancer cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis
  • Cannabidiol* / pharmacology
  • Glutathione / metabolism
  • Humans
  • Male
  • Oxidative Stress
  • Prostatic Neoplasms* / pathology

Substances

  • Cannabidiol
  • Glutathione

Grants and funding

This work was supported by Zhejiang Medical and Health Science Project (2023RC114 to Jie Li). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.